CSCR
MCID: CNT060
MIFTS: 41

Central Serous Chorioretinopathy (CSCR)

Categories: Bone diseases, Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 53 59 72
Central Serous Chorioretinopathy After Bone Marrow Transplantation 53
Central Serous Choroidopathy 53
Cscr 59

Characteristics:

Orphanet epidemiological data:

59
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

ICD10 via Orphanet 34 H35.7
UMLS via Orphanet 73 C0730328
Orphanet 59 ORPHA443079
UMLS 72 C0730328

Summaries for Central Serous Chorioretinopathy

NIH Rare Diseases : 53 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina, the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor. Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and kuhnt-junius degeneration. An important gene associated with Central Serous Chorioretinopathy is SERPINE1 (Serpin Family E Member 1), and among its related pathways/superpathways are Staphylococcus aureus infection and Complement and coagulation cascades. The drugs Verteporfin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone, and related phenotype is renal/urinary system.

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.4 CFH ARMS2
2 kuhnt-junius degeneration 31.0 CFH ARMS2
3 multifocal choroiditis 30.9 CFH ARMS2
4 kidney disease 29.2 SERPINE1 NR3C2 CFH
5 bestrophinopathy, autosomal recessive 11.8
6 retinal detachment 11.2
7 macular degeneration, age-related, 1 10.8
8 microvascular complications of diabetes 5 10.8
9 scotoma 10.7
10 macular retinal edema 10.7
11 periodontal ehlers-danlos syndrome 10.6
12 sleep apnea 10.6
13 uveitis 10.6
14 helicobacter pylori infection 10.5
15 vogt-koyanagi-harada disease 10.5
16 retinal disease 10.5
17 eye disease 10.5
18 refractive error 10.5
19 hydrops, lactic acidosis, and sideroblastic anemia 10.5
20 retinal vascular disease 10.5
21 neuroretinitis 10.4
22 myopia 10.4
23 conn's syndrome 10.4
24 neuritis 10.4
25 retinitis 10.4
26 retinal degeneration 10.4
27 catastrophic antiphospholipid syndrome 10.4 SERPINE1 CFH
28 fibrinolytic defect 10.4 SERPINE1 PLAT
29 coronary heart disease 1 10.4
30 impotence 10.4
31 ulcerative colitis 10.4
32 47,xyy 10.4
33 plasminogen activator inhibitor-1 deficiency 10.4 SERPINE1 PLAT
34 argentine hemorrhagic fever 10.4 SERPINE1 PLAT
35 carotid artery thrombosis 10.4 SERPINE1 PLAT
36 acute cor pulmonale 10.4 SERPINE1 PLAT
37 thrombophlebitis 10.4 SERPINE1 PLAT
38 acute pulmonary heart disease 10.4 SERPINE1 PLAT
39 yemenite deaf-blind hypopigmentation syndrome 10.3
40 optic nerve disease 10.3
41 hemangioma 10.3
42 peptic ulcer disease 10.3
43 cataract 10.3
44 lupus erythematosus 10.3
45 coronary thrombosis 10.3 SERPINE1 PLAT
46 chronic venous insufficiency 10.3 SERPINE1 PLAT
47 venous insufficiency 10.3 SERPINE1 PLAT
48 hepatic veno-occlusive disease 10.3 SERPINE1 PLAT
49 retinal drusen 10.3 CFH ARMS2
50 vein disease 10.3 SERPINE1 PLAT

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

MGI Mouse Phenotypes related to Central Serous Chorioretinopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.92 C4B CFH NR3C2 SERPINE1

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verteporfin Approved, Investigational Phase 4 129497-78-5
2
Bevacizumab Approved, Investigational Phase 4 216974-75-3
3
Eplerenone Approved Phase 4 107724-20-9 150310 443872
4
Ranibizumab Approved Phase 4 347396-82-1 459903
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7 Photosensitizing Agents Phase 4
8 Dermatologic Agents Phase 4
9 Angiogenesis Inhibitors Phase 4
10 Angiogenesis Modulating Agents Phase 4
11 Mitogens Phase 4
12 Antineoplastic Agents, Immunological Phase 4
13 Endothelial Growth Factors Phase 4
14 Antihypertensive Agents Phase 4
15 diuretics Phase 4
16 Diuretics, Potassium Sparing Phase 4
17 Natriuretic Agents Phase 4
18 Hormones Phase 4
19 Mineralocorticoid Receptor Antagonists Phase 4
20 Hormone Antagonists Phase 4
21 Mineralocorticoids Phase 4
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
23 Immunosuppressive Agents Phase 4
24 Immunologic Factors Phase 4
25 Anti-Inflammatory Agents Phase 4
26 glucocorticoids Phase 4
27 triamcinolone acetonide Phase 4
28 Triamcinolone diacetate Phase 4
29 Triamcinolone hexacetonide Phase 4
30 Pharmaceutical Solutions Phase 4
31
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
32
leucovorin Approved Phase 2 58-05-9 143 6006
33
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
34
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
35
Zinc Approved, Investigational Phase 2 7440-66-6 32051
36
Copper Approved, Investigational Phase 2 7440-50-8 27099
37
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
38
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
39
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
40
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
41
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
42
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
43
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
44
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
45
Spironolactone Approved Phase 1, Phase 2 1952-01-7, 52-01-7 5833
46
Brinzolamide Approved Phase 2 138890-62-7 68844
47
Finasteride Approved Phase 2 98319-26-7 57363
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 11103-57-4, 68-26-8 9904001 445354

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
2 A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy Completed NCT01574430 Phase 4
3 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
4 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
5 Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial) Recruiting NCT03079141 Phase 4 Eplerenone
6 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
7 Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis Recruiting NCT03586687 Phase 4 Triamcinolone
8 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
9 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
10 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
11 A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Completed NCT02735213 Phase 2, Phase 3
12 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
13 Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
14 Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
15 Eplerenone for Central Serous Chorioretinopathy: A Pilot Study Completed NCT01822561 Phase 2 Eplerenone 50mg
16 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
17 Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
18 A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole. Completed NCT00211393 Phase 2 ketoconazole
19 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
20 Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
21 Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
22 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC) Completed NCT02354170 Phase 2 Mifepristone;Placebo
23 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
24 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial Completed NCT00987077 Phase 2
25 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
26 Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
27 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
28 Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois Completed NCT01552044 Phase 1, Phase 2 Spironolactone;Placebo
29 Phase 2 Study of Non-damaging Retinal Laser Therapy Using PASCAL Laser With Endpoint Management Software for Macular Diseases Recruiting NCT01975103 Phase 2
30 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Not yet recruiting NCT03542006 Phase 2 Brinzolamide Ophthalmic
31 Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
32 Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid. Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
33 Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy Completed NCT02036632 Phase 1
34 Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab Unknown status NCT00864773
35 Multimodal Imaging in Central Serous Chorioretinopathy Unknown status NCT02889185
36 Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy Unknown status NCT02815176
37 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863
38 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992
39 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884
40 Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease Unknown status NCT02443129
41 Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration Unknown status NCT01115231
42 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 25mg Eplerenone;Placebo
43 Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology Completed NCT01610804
44 Persona of Central Serous Chorioretinopathy Completed NCT02819622
45 Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy Completed NCT03497000
46 Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis Completed NCT01378130
47 Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Completed NCT01434095
48 Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
49 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Completed NCT01327170
50 Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Completed NCT01019668 Verteporfin PDT, half-dose;verteporfin PDT, half-fluence

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

41
Eye, Retina, Bone, Bone Marrow, Brain, Endothelial, Testes

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(show top 50) (show all 1800)
# Title Authors PMID Year
1
A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. 38
30710172 2019
2
Serous macular detachment in nanophthalmos: A manifestation of pachychoroid spectrum. 38
31384695 2019
3
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERISTICS OF POLYPOIDAL CHOROIDAL VASCULOPATHY SECONDARY TO CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 38
29965937 2019
4
Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). 38
31037488 2019
5
Spectrum of choroidal neovascularisation associated with dome-shaped macula. 38
30327318 2019
6
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. 38
30355720 2019
7
Multicolor imaging in central serous chorioretinopathy - a quantitative and qualitative comparison with fundus autofluorescence. 38
31409843 2019
8
Expanding the OCT Spectrum of Acute Central Serous Chorioretinopathy: The Stalagmite-Stalactite Pattern. 38
31383396 2019
9
Concentric retinal pigment epithelium tear in central serous chorioretinopathy. 38
31332124 2019
10
Elevated Steroid Hormone Levels in Active Chronic Central Serous Chorioretinopathy. 38
31387112 2019
11
Central Serous Chorioretinopathy Following Intravitreal Dexamethasone Implant. 38
31389218 2019
12
Angiotensin II and aldosterone in retinal vasculopathy and inflammation. 38
31425690 2019
13
Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. 38
31401003 2019
14
COMBINING EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY WITH STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY AND BLOOD FLOW ANALYSIS FOR DETECTING CHOROIDAL NEOVASCULAR COMPLEXES IN PIGMENT EPITHELIAL DETACHMENTS. 38
29863533 2019
15
Test performance of optical coherence tomography angiography in detecting retinal diseases: a systematic review and meta-analysis. 38
30971815 2019
16
Flat irregular pigment epithelium detachment in central serous chorioretinopathy: Correlation with choroidal neovascular membrane. 38
31332125 2019
17
Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serious Chorioretinopathy. 38
31274738 2019
18
Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. 38
31367848 2019
19
Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy. 38
31037490 2019
20
TRANSIENT PARADOXICAL WORSENING OF VISION DUE TO GRAVITATIONAL SHIFT OF SUBRETINAL FLUID AFTER PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. 38
31313703 2019
21
Retinal pigment epithelium apertures as a late complication of longstanding serous pigment epithelium detachments in chronic central serous chorioretinopathy. 38
31267093 2019
22
Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. 38
31345183 2019
23
Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage. 38
31123815 2019
24
Double-branched and area-constraint fully convolutional networks for automated serous retinal detachment segmentation in SD-OCT images. 38
31200913 2019
25
RESOLUTION OF A SUBFOVEAL CHOROIDAL CAVERN AFTER HALF-DOSE PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. 38
31348118 2019
26
Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy. 38
31268769 2019
27
Comment: Clinical profile of uveitis patients developing central serous chorioretinopathy - An experience at a tertiary eye care center in India. 38
31238489 2019
28
Central serous chorioretinopathy: Towards an evidence-based treatment guideline. 38
31319157 2019
29
Optical coherence tomography angiography versus fluorescein angiography in diagnosing choroidal neovascularization in chronic central serous chorioretinopathy. 38
31238419 2019
30
Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. 38
31256613 2019
31
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. 38
31126617 2019
32
Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. 38
31267094 2019
33
INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 38
29554076 2019
34
ASSESSMENT OF CENTRAL SEROUS CHORIORETINOPATHY DEPICTED ON COLOR FUNDUS PHOTOGRAPHS USING DEEP LEARNING. 38
31283737 2019
35
Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. 38
30824822 2019
36
Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. 38
30378259 2019
37
Hair cortisol concentration in patients with active central serous chorioretinopathy is elevated - a pilot study. 38
30565878 2019
38
Investigating the Hypothesis of Stress System Dysregulation as a Risk Factor for Central Serous Chorioretinopathy: A Literature Mini-Review. 38
30624085 2019
39
Optical Coherence Tomography Angiography for Diagnosis of Choroidal Neovascularization in Chronic Central Serous Chorioretinopathy after Photodynamic Therapy. 38
31227727 2019
40
Optical Coherence Tomography Angiography to Assess Vascular Remodeling of the Choriocapillaris After Low-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. 38
31163282 2019
41
NGRID: A novel platform for detection and progress assessment of visual distortion caused by macular disorders. 38
31279165 2019
42
Rates of Serious Complications Estimated by the ACS-NSQIP Surgical Risk Calculator in Predicting Oncologic Outcomes of Patients Treated with Pancreaticoduodenectomy for Pancreatic Head Cancer. 38
30465189 2019
43
Generation of an E. coli platform strain for improved sucrose utilization using adaptive laboratory evolution. 38
31255177 2019
44
Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy. 38
29916122 2019
45
CORRELATIONS BETWEEN CHANGES IN PHOTORECEPTOR LAYER AND OTHER CLINICAL CHARACTERISTICS IN CENTRAL SEROUS CHORIORETINOPATHY. 38
29401176 2019
46
USE OF CHOROIDAL VASCULARITY INDEX FOR CHOROIDAL STRUCTURAL EVALUATION IN CENTRAL SEROUS CHORIORETINOPATHY WITH CHOROIDAL NEOVASCULARIZATION. 38
31259812 2019
47
Peripheral retinal avascularity and capillary leakage in central serous chorioretinopathy. 38
31317104 2019
48
Clinical characteristics of pachydrusen in central serous chorioretinopathy. 38
30852634 2019
49
Discrepancy in current central serous chorioretinopathy classification. 38
30002069 2019
50
Sensitivity and Specificity of Potential Diagnostic Features Detected Using Fundus Photography, Optical Coherence Tomography, and Fluorescein Angiography for Polypoidal Choroidal Vasculopathy. 38
30973593 2019

Variations for Central Serous Chorioretinopathy

Expression for Central Serous Chorioretinopathy

Search GEO for disease gene expression data for Central Serous Chorioretinopathy.

Pathways for Central Serous Chorioretinopathy

Pathways related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.14 CFH C4B
2 11.07 SERPINE1 PLAT CFH C4B
3 11.04 SERPINE1 PLAT
4 10.07 SERPINE1 PLAT

GO Terms for Central Serous Chorioretinopathy

Cellular components related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.02 SLC7A5 SERPINE1 PLAT CFH C4B

Biological processes related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 complement activation GO:0006956 8.96 CFH C4B
2 fibrinolysis GO:0042730 8.62 SERPINE1 PLAT

Sources for Central Serous Chorioretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....